panorama™
natera prenatal screen

Why Panorama?

Validated. Published. Trusted.

Panorama™ is evaluated in 12 peer-reviewed publications and >60,000 pregnancies.*

Validated in high-risk and low-risk patients.

"This noninvasive prenatal screen performed with high sensitivity and specificity in high-risk and low-risk cohorts... The SNP-based method resulted in improved overall performance over quantitative methods."

– Pergament et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. *Obstet Gynecol,* Aug 2014; 124 (2 Pt 1):210-8. (Study of 1,064 samples, mixture of high-risk and low-risk.))

External validation of SNP-based NIPT.

"cfDNA testing in maternal blood using targeted sequencing of polymorphic loci at chromosomes 13, 18, 21, X and Y hold promise for accurate detection of fetal autosomal trisomies, sex chromosome aneuploidies and triploidy."

– Nicolaides, K. H. et al. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X and Y. *Prenat Diagn,* 2013;33: 1-5.

Extensive clinical experience supports usage in all patients.

"Clinical performance of SNP-based NIPT in a mixed high- and low-risk population is consistent with performance in validation studies... This study supports the use of NIPT as a first line screening test for aneuploidy in all patients."

– Dar et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. *Am J Obstet Gynecol,* 2014;211 :527.e1-17. (Study of 28,739 samples from both high-risk and low-risk pregnancies.)

Highly accurate screening for vanishing twins, reducing false positives.

"The ability to detect vanishing twin pregnancies is clinically important as it will reduce the number of false-positive results... "

– Curnow et al. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism based noninvasive prenatal test. *Am J Obstet Gynecol,* 2014;211 :x.ex-x.ex. (Study of 30,795 reported clinical cases.)

panorama™
natera prenatal screen

Screens for microdeletions with high accuracy.

"SNP-based noninvasive prenatal microdeletion screening is highly accurate... for the general pregnant population should be considered."

– Wapner et al. Expanding the scope of non-invasive prenatal testing: Detection of fetal microdeletion syndromes. *Am J Obstet Gynecol,* 2015;doi: 10.1016/j.ajog.2014.11.041. (Study of 469 samples.)

Powerful method for sex chromosome analysis.

"Although existing non-invasive prenatal testing methods demonstrate high sensitivity and specificity when detecting autosomal trisomies, none accomplishes similar levels of accuracy with sex chromosome aneuploidy detection."

– Samango-Sprouse et al. SNP-based method detects sex chromosome aneuploidies with high accuracy. *Prenat Diag,* 2013;33:1-7. (Study of 16 aneuploid and 185 euploid samples.)

Can identify molar pregnancies.

"... a noninvasive test that can readily distinguish between a missed miscarriage and a CMP (complete molar pregnancy) could be useful in the diagnosis and management of women who present with overlapping signs and symptoms, particularly early in pregnancy."

– Simon, A.L. et al. Detection of a complete molar pregnancy by single nucleotide polymorphism-based noninvasive prenatal testing. *Ultrasound Obstet Gynecol,* in press.

Large follow up study for 22q11.2 deletion syndrome, the most common microdeletion syndrome.

"In this study, 21,948 samples were submitted for screening for 22q11.2 deletion syndrome using a SNP-based NIPT and subsequently evaluated."

– Gross et al. Clinical Experience with Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Screening for 22q11.2 Deletion Syndrome. *Ultrasound Obstet Gynecol,* 2015; doi: 10.1002/uog.15754. Epub 2015 Sep 23. (Study of 20,776 samples)

No-call rate and fetal fraction threshold reduced in the updated version.

"An observed no-call rate of 2.3%... The no-call threshold for sample calling was reduced to 2.8% fetal fraction."

– Ryan et al. Validation of an Enhanced Version of a Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Detection of Fetal Aneuploidies. *Fetal Diagnosis and Therapy,* 2016; doi:10.1159 (Study of 587 samples)

***References:** For a list of complete citations please visit www.natera.com/panorama-test/references-16

natera™
Conceive. Deliver.

Panorama: part of the Natera family of products

panorama™ natera prenatal screen | horizon™ natera carrier screen | spectrum™ natera preimplantation genetics (PGS/PGD) | anora™ natera miscarriage test (POC)

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1-650-249-9090 | Fax 1-650-730-2272

PAN-MD-PUBSELLSHEET-V3-INTL (4/2016) NAT-801343